

Physician Publications and Presentations

Thoracic • Mehkail

Presentations

Wakelee H, Zvirbule Z, De Braud F, Kingsley CD, **Mekhail T**, Lowe T, Schütte W, Lena H, Lawler W, Braiteh F, Cosgriff T, Kaen D, Boyer M, Hsu J, Phan S, Novello S; "Efficacy and Safety of Onartuzumab in Combination with First-Line Bevacizumab - or Pemetrexed-Based Chemotherapy Regimens in Advanced Non-Squamous Non-Small-Cell Lung Cancer"; Clin Lung Cancer Oct. 2016; pii: S1525-7304(16)30241-8. doi: 10.1016/j.clc.2016.09.013. [Epub ahead of print].

Waterhouse D, Horn L, Reynolds C, Spigel D, Chandler J, **Mekhail T**, Mohamed M, Creelan B, Blankstein KB, Nikolinakos P, Mcleod MJ, Li A, Waxman IM, Aanur N, Agrawal S, Richardet E; "P2.33: Safety Profile of Nivolumab Administered as 30-Minute (MIN) Infusion: Analysis of Data from Checkmate 153: Track: Immunotherapy"; J Thorac Oncol. Oct. 2016;11(10S): S236. doi: 10.1016/j.jtho.2016.08.104. No abstract available.

Solomon BJ, Cappuzzo F, Felip E, Blackhall FH, Costa DB, Kim DW, Nakagawa K, Wu YL, **Mekhail T**, Paolini J, Tursi J, Usari T, Wilner KD, Selaru P, Mok TS; "Intracranial Efficacy of Crizotinib Versus Chemotherapy in Patients with Advanced ALK-Positive Non-Small-Cell Lung Cancer: Results from PROFILE 1014"; J Clin Oncol. Aug. 2016; 34(24):2858-65. doi: 0.1200/JCO.2015.63.5888.

Shaw AT, Gandhi L, Gadgeel S, Riely GJ, Cetnar J, West H, Camidge DR, **Socinski MA**, Chiappori A, **Mekhail T**, Chao BH, Borghaei H, Gold KA, Zeaiter A, Bordogna W, Balas B, Puig O, Henschel V, Ou SH; study investigators; "Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial"; Lancet Oncol. Feb. 2016;17(2):234-42. doi: 10.1016/S1470-2045(15)00488-X.

Ou SH, Ahn JS, De Petris L, Govindan R, Yang JC, Hughes B, Lena H, Moro-Sibilot D, Bearz A, Ramirez SV, **Mekhail T**, Spira A, Bordogna W, Balas B, Morcos PN, Monnet A, Zeaiter A, Kim DW; "Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study"; J Clin Oncol. March 2016; 34(7):661-8. doi: 10.1200/JCO.2015.63.9443.

Efficacy and Safety of Onartuzumab in Combination With First-Line Bevacizumab- or Pemetrexed-Based Chemotherapy Regimens in Advanced Non-Squamous Non-Small-Cell Lung Cancer. Wakelee H, Zvirbule Z, De Braud F, Kingsley CD, **Mekhail T**, Lowe T, Schütte W, Lena H, Lawler W, Braiteh F, Cosgriff T, Kaen D, Boyer M, Hsu J, Phan S, Novello S. Clin Lung Cancer. 2016 Oct 19. pii: S1525-7304(16)30241-8. doi: 10.1016/j.clc.2016.09.013. [Epub ahead of print]

P2.33: Safety Profile of Nivolumab Administered as 30-Minute (MIN) Infusion: Analysis of Data From Checkmate 153: Track: Immunotherapy. Waterhouse D, Horn L, Reynolds C, Spigel D, Chandler J, **Mekhail T**, Mohamed M, Creelan B, Blankstein KB, Nikolinakos P, Mcleod MJ, Li A, Waxman IM, Aanur N, Agrawal S, Richardet E. J Thorac Oncol. 2016 Oct;11(10S):S236. doi: 10.1016/j.jtho.2016.08.104. No abstract available.

Intracranial Efficacy of Crizotinib Versus Chemotherapy in Patients With Advanced ALK-Positive Non-Small-Cell Lung Cancer: Results From PROFILE 1014. Solomon BJ, Cappuzzo F, Felip E, Blackhall FH, Costa DB, Kim DW, Nakagawa K, Wu YL, **Mekhail T**, Paolini J, Tursi J, Usari T, Wilner KD, Selaru P, Mok TS. J Clin Oncol. 2016 Aug 20;34(24):2858-65. doi: 10.1200/JCO.2015.63.5888.

Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial. Shaw AT, Gandhi L, Gadgeel S, Riely GJ, Cetnar J, West H, Camidge DR, **Socinski MA**, Chiappori A, **Mekhail T**, Chao BH, Borghaei H, Gold KA, Zeaiter A, Bordogna W, Balas B, Puig O, Henschel V, Ou SH; study investigators. *Lancet Oncol.* 2016 Feb;17(2):234-42. doi: 10.1016/S1470-2045(15)00488-X.

Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study. Ou SH, Ahn JS, De Petris L, Govindan R, Yang JC, Hughes B, Lena H, Moro-Sibilot D, Bearz A, Ramirez SV, **Mekhail T**, Spira A, Bordogna W, Balas B, Morcos PN, Monnet A, Zeaiter A, Kim DW. *J Clin Oncol.* 2016 Mar 1;34(7):661-8. doi: 10.1200/JCO.2015.63.9443

Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study. Ou SI, Ahn JS, De Petris L, Govindan R, Yang JC, Hughes B, Lena H, Moro-Sibilot D, Bearz A, Ramirez SV, **Mekhail T**, Spira A, Bordogna W, Balas B, Morcos PN, Monnet A, Zeaiter A, Kim DW. *J Clin Oncol.* 2015 Nov 23. pii: JCO639443. [Epub ahead of print]

Randomized Phase II Trial of Erlotinib Beyond Progression in Advanced Erlotinib-Responsive Non-Small Cell Lung Cancer. Halmos B, Pennell NA, Fu P, Saad S, Gadgeel S, Otterson GA, **Mekhail T**, Snell M, Kuebler JP, Sharma N, Dowlati A. *Oncologist.* 2015 Nov;20(11):1298-303. doi: 10.1634/theoncologist.2015-0136. Epub 2015 Aug 25.

Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, **Mekhail T**, Felip E, Cappuzzo F, Paolini J, Usari T, Iyer S, Reisman A, Wilner KD, Tursi J, Blackhall F; PROFILE 1014 Investigators. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. *N Engl J Med.* 2014 Dec 4; 371(23):2167-77. doi: 10.1056/NEJMoa1408440.

Wakelee H, Zvirbule Z, Braud F, Kingsley D, **Mekhail T**, Schütte W, Lena H, Lawler W, Braitheh F, Cosgriff T, Kaen D, Boyer M, Hsu J, Phan S, Novello S. Efficacy and safety of onartuzumab in combination with first-line bevacizumab- or pemetrexed-based chemotherapy regimens in advanced non-squamous non-small-cell lung cancer (nsNSCLC): results from a phase II, placebo-controlled study (GO27821). 2014 Chicago Multidisciplinary Symposium in Thoracic Oncology.

Nakagawa L, Mok T, Kim D, Wu Y, Solomon B, **Mekhail T**, Felip E, Cappuzzo F, Paolini J, Usari T, Tursi J, Blackhall F. First-line crizotinib vs. pemetrexed + cisplatin/carboplatin in Asian patients with advanced ALK+ NSCLC in PROFILE 1014. 12th Annual Meeting JSMO, July 2014.

.Mok T, Kim D, Wu Y, Solomon B, Nakagawa K, **Mekhail T**, Felip E, Cappuzzo F, Paolini J, Usari T, Tursi J, Blackhall F. First-line crizotinib versus pemetrexed–cisplatin or pemetrexed–carboplatin in patients (pts) with advanced ALK-positive non-squamous non-small cell lung cancer (NSCLC): results of a phase III study (PROFILE 1014) *J Clin Oncol* 32:5s, 2014 (suppl; abstr 8002).

Sharma N, Pennell N, Nickolich M, Halmos B, Ma P, **Mekhail T**, Fu P, Dowlati A. Phase II trial of sorafenib in conjunction with chemotherapy and as maintenance therapy in extensive-stage small cell lung cancer. *Invest New Drugs.* 2014 Apr; 32(2):362-8. Epub 2014 Jan 15.

Blackhall FH, Felip E, Cappuzzo F, Kim DW, Wu Y, Solomon B, Nakagawa K, **Mekhail T**, Paolini J, Usare T, Iyer S, Reisman A, Wilner K, Tursi J, Mok TS. Impact of Crizotinib on Patient-reported Symptoms and Global QOL Compared with Platinum-Based Chemotherapy in a Phase III Study of Treatment-Naïve Advanced ALK-positive NSCLC. ESMO 2014, Poster Discussion.

Soria J, Sequist LV, Goldman JW, Wakelee HA, Gadgeel SM, Varga A, Yu HA, Solomon BJ, Ou SH, Papadimitrakopoulou V, Oxnard GR, Horn L, Dziadziuszko R, Chao B, Spira AI, Liu S, **Mekhail T**, Matheny S, Litten J, Camidge RD. Title: Interim phase 2 results of study CO-1686-008: A phase 1/2 study of the irreversible, mutant selective, EGFR inhibitor rociletinib (CO-1686) in patients with advanced non small cell lung cancer. Plenary Session, 2014 EORTC-NCI-AACR, Barcelona, Spain.

Mekhail T, Waterhouse, D. M., Hadley, T. J., Webb, C. D., Burris, H.A., Hainsworth, J. D., Greco, A. , Spigel, D. R. First-line carboplatin, pemetrexed, and panitumumab in patients with advanced nonsquamous KRAS wild type (WT) non-small cell lung cancer (NSCLC). *Journal of Clinical Oncology* 31, 2013 (supplement)

Halmos B., Penell, N., Otterson G., Gadgeel, S. , **Mekhail, T.**, et al. Erlotinib beyond progression study: Randomized phase II study comparing chemotherapy plus erlotinib with chemotherapy alone in EGFR tyrosine kinase inhibitor (TKI)-responsive, non-small cell lung cancer (NSCLC) that subsequently progresses. *Journal of Clinical Oncology* 31, 2013 (supplement).

Jones, C. V., Du, L., Elson, P., **Mekhail, T.**, Pennel, N. , Sadraie, N. Predictors of outcome for pemetrexed (PEM) in metastatic NSCLC (mNSCLC). *Journal of Clinical Oncology* 31, 2013 (supplement).

Fakhreijahani, F., Hashemi Sadraei, N., **Mekhail T.** The role of consolidation treatment in locally advanced unresectable NSCLC. *Current Oncology Report*, 2013, Aug: 15(4):424-32.

Mekhail T, Waterhouse, D. M., Hadley, T. J., Webb, C. D., Burris, H.A., Hainsworth, J. D., Greco, A. , Spigel, D. R. First-line carboplatin, pemetrexed, and panitumumab in patients with advanced nonsquamous KRAS wild type (WT) non-small cell lung cancer (NSCLC). 2013 ASCO Annual Meeting.

Halmos B., Penell, N., Otterson G., Gadgeel, S. , **Mekhail, T.**, et al. Erlotinib beyond progression study: Randomized phase II study comparing chemotherapy plus erlotinib with chemotherapy alone in EGFR tyrosine kinase inhibitor (TKI)-responsive, non-small cell lung cancer (NSCLC) that subsequently progresses. 2013 ASCO Annual Meeting.

Mikhail M, Mekhail Y, **Mekhail T.** Thymic neoplasms: a clinical update. *Curr Oncol Rep*. 2012 Aug;14(4):350-8. Review.

Schwandt A, **Mekhail T**, Halmos B, O'Brien T, Ma PC, Fu P, Ivy P, Dowlati A. Phase-II trial of rebeccamycin analog, a dual topoisomerase-I and -II inhibitor, in relapsed "sensitive" small cell lung cancer. *J Thorac Oncol*. 2012 Apr;7(4):751-4.

Mazzone P, **Mekhail T.** Current and emerging medical treatments for non-small cell lung cancer: a primer for pulmonologists. *Respir Med*. 2012 Apr;106(4):473-92.. Epub 2011 Nov 25. Review.

Mazzone PJ, Wang XF, Xu Y, **Mekhail T**, Beukemann MC, Na J, Kemling JW, Suslick KS, Sasidhar M. Exhaled breath analysis with a colorimetric sensor array for the identification and characterization of lung cancer. *J Thorac Oncol*. 2012 Jan;7(1):137-42..

Rosen LS, Senzer N, **Mekhail T**, Ganapathi R, Chai F, Savage RE, Waghorne C, Abbadessa G, Schwartz B, Dreicer R. A phase I dose-escalation study of Tivantinib (ARQ 197) in adult patients with metastatic solid tumors. *Clin Cancer Res*. 2011 Dec 15;17(24):7754-64.

Garcia JA, **Mekhail T**, Elson P, Wood L, Bukowski RM, Dreicer R, Rini BI. Phase I/II trial of subcutaneous interleukin-2, granulocyte-macrophage colony-stimulating factor and interferon- in patients with metastatic renal cell carcinoma. *BJU Int*. 2012 Jan;109(1):63-9.. Epub 2011 Jan 18.

Santos ES, **Mekhail T.** A strong step forward in maintenance therapy for non-small cell lung cancer treatment. *Transl Lung Cancer Res* 2012;1(2):99-101.

Rosen LS, Senzer N, **Mekhail T**, Ganapathi R, Chai F, Savage RE, Waghorne C, Abbadessa G, Schwartz B, Dreicer R. A phase I dose-escalation study of Tivantinib (ARQ 197) in adult patients with metastatic solid tumors. *Clin Cancer Res*. 2011 Dec 15;17(24):7754-64. Epub 2011 Oct 5.

Mekhail T, Sombeck M, Sollaccio R. Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study. *Curr Oncol Rep.* 2011 Aug;13(4):255-8. No abstract available.

Garcia JA, **Mekhail T**, Elson P, Triozzi P, Nemec C, Dreicer R, Bukowski RM, Rini BI. Clinical and immunomodulatory effects of bevacizumab and low-dose interleukin-2 in patients with metastatic renal cell carcinoma: results from a phase II trial. *BJU Int.* 2011 Feb;107(4):562-70. doi: 10.1111/j.1464-410X.2010.09573.x. Epub 2010 Sep 14.

Murthy SC, Reznik SI, Ogwudu UC, Farver CF, Arrossi A, Batizy LH, Nowicki ER, **Mekhail TM**, Mason DP, Rice TW, Blackstone EH. Winning the battle, losing the war: the noncurative "curative" resection for stage I adenocarcinoma of the lung. *Ann Thorac Surg.* 2010 Oct;90(4):1067-74.

Garcia JA, **Mekhail T**, Elson P, Triozzi P, Nemec C, Dreicer R, Bukowski RM, Rini BI. Clinical and immunomodulatory effects of bevacizumab and low-does interleukin-2 in patients with metastatic renal cell carcinoma: results from a phase II trial. *BJU Int.* 2011 Feb;107(4):562-70. doi: 10.1111/j.1464-410X.2010.09573.x. Epub 2010 Sep 14 .

Luszczek W, Cheryath V, **Mekhail TM**, Borden EC. Combinations of DNA methyltransferase and histone deacetylase inhibitors induce DNA damage in small cell lung cancer cells: correlation of resistance with IFN-stimulated gene expression. *Mol Cancer Ther.* 2010 Aug;9(8):2309-21. Epub 2010 Aug 3.

Mekhail T, Masson E, Fischer BS, Gong J, Iyer R, Gan J, Pursley J, Patricia D, Williams D, Ganapathi R. Metabolism, excretion, and pharmacokinetics of oral brivanib in patients with advance or metastatic solid tumors. *Drug Metab Dispos.* 2010 Nov;38(11):1962-6. Epub 2010 Jul 29.
Mekhail T, Boyer J. Limited resection for early-stage lung cancer. *Curr Oncol Rep.* 2010 Sep;12(5):285-7.

Small vessel ischemic disease of the brain and brain metastases in lung cancer patients. Mazzone PJ, Marchi N, Fazio V, Taylor JM, Masaryk T, Bury L, **Mekhail T**, Janigro D. *PLoS One.* 2009 Sep 30;4(9):e7242.

A phase I study of sunitinib plus bevacizumab in advanced solid tumors. Rini BI, Garcia JA, Cooney MM, Elson P, Tyler A, Beatty K, Bokar J, **Mekhail T**, Bukowski RM, Budd GT, Triozzi P, Borden E, Ivy P, Chen HX, Dolwati A, Dreicer R. *Clin Cancer Res.* 2009 Oct 1;15(19):6277-83. Epub 2009 Sep 22.

A comparison of two stereotactic body radiation fractionation schedules for medically inoperable stage I non-small cell lung cancer: the Cleveland Clinic experience. Stephans KL, Djemil T, Reddy CA, Gajdos SM, Kolar M, Mason D, Murthy S, Rice TW, Mazzone P, Machuzak M, **Mekhail T**, Videtic GM. *J Thorac Oncol.* 2009 Aug;4(8):976-82.

Investigational agents in the management of non-small cell lung cancer. Pennell NA, **Mekhail T**. *Curr Oncol Rep.* 2009 Jul;11(4):275-84. Review.

Gender, race, and survival: a study in non-small-cell lung cancer brain metastases patients utilizing the radiation therapy oncology group recursive partitioning analysis classification. Videtic GM, Reddy CA, Chao ST, Rice TW, Adelstein DJ, Barnett GH, **Mekhail TM**, Vogelbaum MA, Suh JH. *Int J Radiat Oncol Biol Phys.* 2009 Nov 15;75(4):1141-7. Epub 2009 Mar 26.